GlassScriptPhysician profile
Claire E Sellers
NPI 1316237860
$3,037.94
in general payments reported to CMS, 2019-2025
35 companies · $769 in 2025
The $769 reported for 2025 was more than what 88% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $406 · 2020: $169 · 2021: $163 · 2022: $368 · 2023: $435 · 2024: $729 · 2025: $769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,842 · Education: $90.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,841.83 |
| Education | $90.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $512.17 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $266.82 | 2022-2025 | |
| Evofem Biosciences, INC. | $195.78 | 2022-2025 | Phexxi, Phexx, Solosec |
| Coopersurgical, INC. | $182.13 | 2020-2025 | Paragard T 380a, Paragard T 380a |
| Astellas Pharma US INC | $178.05 | 2024-2025 | Veozah |
| Abbvie INC. | $163.99 | 2019-2023 | Lo Loestrin Fe, Ubrelvy, Orilissa |
| Pfizer INC. | $160.69 | 2019-2024 | |
| Shield Therapeutics INC | $152.43 | 2024-2025 | |
| Exeltis, USA INC. | $146.87 | 2023-2025 | Slynd |
| Biogen, INC. | $127.36 | 2024-2025 | Zurzuvae |
| Hologic Sales and Service, LLC | $104.75 | 2023-2025 | Acessa Provu System, Myosure Tissue Removal Device, Fetal Fibronectin Enzyme Immunoassay |
| Organon LLC | $87.80 | 2022-2025 | Nexplanon |
| Daiichi Sankyo INC. | $63.10 | 2019-2021 | |
| Duchesnay USA Incorporated | $51.34 | 2019 | |
| Amgen INC. | $50.71 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma Global Development | $50.06 | 2024 | Veozah |
| Merck Sharp & Dohme LLC | $49.44 | 2019-2022 | |
| Roche Diagnostics Corporation | $48.83 | 2019-2020 | |
| Aspira Women'S Health INC | $47.65 | 2021 | |
| Allergan, INC. | $44.75 | 2019-2020 | |
| Applied Medical Resources Corporation | $41.09 | 2023 | Gelpoint V-Path |
| Therapeuticsmd, INC. | $40.83 | 2019-2021 | |
| Minerva Surgical, INC | $40.27 | 2019 | |
| Avion Pharmaceuticals | $29.82 | 2020-2021 | |
| Mylan Pharmaceuticals INC. | $29.62 | 2019 | |
| Amag Pharmaceuticals, INC. | $25.90 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $21.76 | 2025 | |
| Sumitomo Pharma America, INC. | $20.87 | 2024 | Gemtesa |
| Sage Therapeutics, LLC | $19.65 | 2022 | |
| Alexion Pharmaceuticals, INC. | $18.66 | 2021 | |
| Lilly USA, LLC | $16.95 | 2020 | |
| Smith+Nephew, INC. | $16.59 | 2019 | |
| Lsi Solutions INC | $16.39 | 2024 | Fornisee |
| Laborie Medical Technologies Corp. | $14.82 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claire Sellers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.